Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Immunotherapy|August 3, 2012
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomesNicole Kounalakis, Dexiang Gao, Rene Gonzalez, et al.
Patient Education and Counseling|May 8, 2013
Bridging the transition from cancer patient to survivor: pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) programKathleen Garrett, Sonia Okuyama, Whitney Jones, et al.
Dermatology and Therapy|September 7, 2021
Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc AnalysisRalf Gutzmer, Carmen Loquai, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2014
Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of diseaseMargaret McCusker, Nicole Basset-Seguin, Reinhard Dummer, et al.
Annals of Surgical Oncology|June 27, 2007
Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patientsMartin D McCarter, Joel Baumgartner, Guillermo A Escobar, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Spatial mapping of polymicrobial communities reveals a precise biogeography associated with human dental cariesDongyeop Kim, Juan P Barraza, Rodrigo A Arthur, et al.
Radiation Oncology (London, England)|April 12, 2011
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local controlMichelle A Stinauer, Brian D Kavanagh, Tracey E Schefter, et al.
Biology Open|December 6, 2012
ABT-737 synergizes with Bortezomib to kill melanoma cellsSteven N Reuland, Nathaniel B Goldstein, Katie A Partyka, et al.
Nuclear Medicine Communications|October 7, 2015
Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanomaRonald J Schmitt, Sarah M Kreidler, Deborah H Glueck, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinibKarl Lewis, Axel Hauschild, James Larkin, et al.
Pageof 5